Category Archives: Health Care

FDA Grants PMA Approval for Hologic’s Aptima® Hepatitis C Quant Dx Assay

Hologic, Inc. (HOLX) declared recently that the United States Food and Drug Administration (FDA) has granted PMA approval for the Company’s hepatitis C virus (HCV) assay for quantitation of HCV viral load and confirming active HCV infection on the fully automated Panther® system.

Abbott (ABT) Declared The Results Of Real-World Use Data

Abbott (ABT) recently declared the results of real-world use data showing that people who scan more frequently using Abbott′s FreeStyle®Libre system spend less time in hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) while having improved average glucose levels.

Extreme Muscle Products Launches First Formulation

Extreme Muscle Products (EMP) recently declared the launch of its first formulation available for purchase, a product called Q-Meric.

EMP is a newly created Colorado-based company focusing on health, wellness and athletic performance, with an emphasis on products that have synergistic effects. This means the ingredients in the products work more effectively together than if taken separately. Q-Meric is a blend of Turmeric, CoenzymeQ10 (CoQ10) and pyrroloquinoline quinone (PQQ).

GB Sciences Files Patent Application for the Treatment of Chronic Arthritis, Crohn’s Disease, Inflammatory Bowel Disease, and Asthma; Proprietary Cannabinoid-Containing Complex Mixtures for the Treatment of Inflammatory Disorders

 GB Sciences, Inc. (OTCQB: GBLX) declared filing the second in a series of patent applications for life science inventions by its wholly-owned partner, Growblox Life Sciences, LLC.

Inflammatory disorders represent a serious health and economic burden in the US with over $200 billion spent annually. GB Sciences’ novel cannabis-based therapies could significantly assist both patients and society. According to the CDC, arthritis affects 22.7% (52.5 million) of adults in the US (2010-2012), and the prevalence is projected to increase to an estimated 26% (78 million of the projected total adult population) by 2040. The total costs associated with arthritis were $128 billion in 2003, and they have been increasing over time. In Addition To, 8.6% (7 million) children and 7.4% (17.8 million) adults had asthma (2014), which costs the US $56 billion per year. Inflammatory Bowel Disease (“IBD”), which includes Crohn’s disease and ulcerative colitis) affected between 1 and 1.3 million people in the US (2007). Per the CDC, IBD is an expensive, chronic disease, which cost the US $11.8 billion in 2008, despite the lower prevalence rates.

Medical Marijuana, Inc. Partner Kannaway® Declares Exclusive Red-Carpet Event in Phoenix, Arizona

 Medical Marijuana, Inc. (OTC: MJNA) declared recently that its partner, Kannaway, LLC, the first hemp lifestyle network to offer cannabidiol (CBD) hemp botanical products, is holding an exclusive Red-Carpet Event in Phoenix, Az., this weekend. The Red-Carpet Event provides an exclusive opportunity to network with top Kannaway leaders, the company’s executive team and fellow business owners.

Attendees will hear from executive team members, counting Kannaway CEO Blake Schroeder, President Brad Tayles and CEO of Kannaway parent company Medical Marijuana, Inc., Dr. Stuart Titus. In Addition To, the Red-Carpet Event will provide Kannaway business owners with exclusive opportunities to accelerate their success as brand ambassadors, by hearing from some of our top leaders and income earners.

Axovant Sciences Declares Dementia Pipeline Updates and Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended December 31, 2016

 Axovant Sciences (NYSE:  AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, recently declared corporate updates and stated financial results for the third fiscal quarter ended December 31, 2016.

Natural Alternatives International, Inc. Declares Fiscal 2017 Q2 Results

Natural Alternatives International, Inc. (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, recently declared net income of $2.5 million, or $0.37 per diluted share, on net sales of $30.6 million for the quarter ended December 31, 2016.

Net sales during the three months ended December 31, 2016 raised $3.6 million, or 13.6%, from $26.9 million recorded in the comparable prior year period. For the quarter ended December 31, 2016, private label contract manufacturing sales raised $2.2 million, or 10.4%, from the comparable quarter last year. Our second quarter fiscal 2017 contract manufacturing sales were favorably influenced because of timing and shipment of orders and new product launches. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue raised 26.5% to $6.7 million during the second quarter of fiscal 2017 as contrast to $5.3 million for the second quarter of fiscal 2016. The increase in CarnoSyn® beta-alanine revenue was mainly because of the addition of new customers and raised material shipments to existing customers.

Vitae Pharmaceuticals, NASDAQ:VTAE, VTAE

Epicore BioNetworks Inc. Reports Quarter Two Results for Fiscal Year 2017

Epicore BioNetworks Inc. (TSXV EBN) stated second quarter revenue of $3.0 million and net income of $0.7 million or $0.03 per share for the period ended December 31, 2016.

Hill-Rom Completes Acquisition Of Mortara Instrument

Hill-Rom Holdings, Inc. (“Hill-Rom”) (NYSE: HRC), has accomplished its acquisition of Mortara Instrument, Inc. (Mortara), for $330 million in cash, mainly financed through a private offering of $300 million of senior unsecured notes. Hill-Rom anticipates the structure of the acquisition will allow the company to qualify for a noteworthytax benefit, which at a net present value of about $40 million reduces the effective purchase price to about $290 million.

Express Scripts Declares 2016 Fourth Quarter and Full Year Results

Express Scripts Holding Company (Nasdaq: ESRX) declared 2016 fourth quarter and full year net income of $1,434.7 million and $3,404.4 million, respectively, or $2.34 and $5.39 per diluted share, respectively. 2016 fourth quarter and full year adjusted earnings per diluted share, as detailed in Table 4, was $1.88 and $6.39, respectively.

“We delivered another year of successful performance, not only through financial results, but by providing innovative solutions to assist our patients and clients drive healthier outcomes and lower drug trends,” said Tim Wentworth, CEO and President. “In a year when the focus on drug pricing has never been greater, Express Scripts has held the 2016 growth rate in drug unit costs to 2.5% and lowered the patients’ share of total drug costs per prescription. The fundamentals of our business remain strong as our clinical focus and unwavering alignment with clients facilitates us to lead the industry in developing innovative value-based solutions that our country needs.”